Tradestie Institutional Equity Comparison Engine

FDMT vs SRPT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SRPT Overall Edge

SRPT Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Sarepta Therapeutics,, Inc. Common Stock (SRPT) driven by superior Valuation, Growth & Margin, Options & Structure while FDMT counters with relative strength in Momentum & Technical. Fundamentally, FDMT trades at N/M Forward P/E with -222.7% operating margin (+4505.6% YoY revenue) versus SRPT at 10.8x Forward P/E and -0.4% operating margin (-4.5% YoY). In options structure, FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro) against SRPT sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner SRPT
FDMT N/M vs SRPT 10.8x Fwd P/E
Growth & Margin Winner SRPT
Op Margin -222.7% vs -0.4% ยท YoY +4505.6% vs -4.5%
Momentum & Technical Winner FDMT
1Y +13.3% vs -15.0% ยท 52W Pos 47% vs 5%
Options & Structure Winner SRPT
BREAKDOWN (10th %ile IV) vs BREAKDOWN (7th %ile IV)
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
1M Return -4.04%
1Y Return +13.33%
Forward P/E N/M
Unified AI Score
42.1 / 100 HOLD
Tech 21.0 Fund 54.0 Flow 66.0 Mom 54.0
SRPT NASDAQ
Sarepta Therapeutics,, Inc. Common Stock
Pharmaceutical Preparations
$15.14
-5.76% 1D
Market Cap $1.7B
1M Return -11.44%
1Y Return -15.02%
Forward P/E 10.8x
Unified AI Score
36.8 / 100 SELL
Tech 29.0 Fund 50.0 Flow 71.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: FDMT +13.33% SRPT -15.02% Spread: +28.35 pp (FDMT Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period FDMT Revenue SRPT Revenue FDMT Op. Margin SRPT Op. Margin Margin Edge
FY2018 N/A $300M N/A -114.1% SRPT
FY2019 $10M $380M -729.4% -185.3% SRPT
FY2020 $10M $460M -424.0% -123.8% SRPT
FY2021 $20M $610M -395.5% -75.1% SRPT
FY2022 $0M $840M -3516.5% -63.5% SRPT
FY2023 $20M $1.14B -544.6% -23.4% SRPT
FY2024 $0M $1.79B -507678.4% 12.2% SRPT
FY2025 $90M $1.86B -187.2% -37.5% SRPT

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: FDMT (3) vs SRPT (6)
Institutional Metric FDMT SRPT Criterion Row Winner
Market Capitalization Scale $669.3M $1.7B Larger Scale SRPT
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M 10.8x Lower Multiple SRPT
Revenue Growth (YoY) Growth +4505.6% -4.5% Higher Growth FDMT
Operating Margin (TTM) Profitability -222.7% -0.4% Higher Margin SRPT
Net Profit Margin Profitability -208.6% -5.9% Higher Margin SRPT
Return on Equity (ROE) Capital Efficiency -56.7% -8.1% Higher ROE SRPT
52-Week Range Position Momentum 47% ($7โ€“$17) 5% ($15โ€“$25) Stronger Trend FDMT
Beta / 30D Volatility Risk Regime 1.89ฮฒ ยท 90% Vol 1.47ฮฒ ยท 58% Vol Lower Realized Risk SRPT
Unified Institutional Score Composite Signal 42.1 / 100 (HOLD) 36.8 / 100 (SELL) Higher Composite FDMT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full FDMT vs SRPT Buy Guide
FDMT BREAKDOWN
62d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live FDMT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SRPT BREAKDOWN
52d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 7th %ile
IV Regime Compressed (<25th %ile)
Live SRPT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither FDMT nor SRPT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.